BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 16182402)

  • 1. Fluoride-Ion-Responsive Sol-Gel Transition in an L-Cysteine/AgNO
    Vishnevetskii DV; Andrianova YV; Polyakova EE; Ivanova AI; Mekhtiev AR
    Gels; 2024 May; 10(5):. PubMed ID: 38786249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technical Considerations, Applications, and Benefits of Organogels in Topical Drug Delivery Systems.
    Yadav A; Jhawat V; Singh RP; Chauhan S; Dutt R; Goyal R; Singh D
    Recent Adv Drug Deliv Formul; 2024; 18(1):12-20. PubMed ID: 38385494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of odd-even effect and intermolecular interactions in 2D molecular layers of bisamide organogelators.
    Kocasoy V; Dedeoglu B; Demir-Ordu O; Aviyente V
    RSC Adv; 2018 Oct; 8(61):35195-35204. PubMed ID: 35547041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid Self-Assembled Gel Beads for Tuneable pH-Controlled Rosuvastatin Delivery.
    Piras CC; Patterson AK; Smith DK
    Chemistry; 2021 Sep; 27(52):13203-13210. PubMed ID: 34346527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Delivery of Neuroactive Drugs via Nasal Delivery with a Self-Healing Supramolecular Gel.
    Wang JT; Rodrigo AC; Patterson AK; Hawkins K; Aly MMS; Sun J; Al Jamal KT; Smith DK
    Adv Sci (Weinh); 2021 Jul; 8(14):e2101058. PubMed ID: 34029010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, Characterization and Biocompatibility of N-palmitoyl L-alanine-based Organogels as Sustained Implants of Granisetron and Evaluation of thier Antiemetic Effect.
    El-Nassan HB; ElMeshad AN; Wadie W; Sayed RH
    Pharm Res; 2018 May; 35(8):149. PubMed ID: 29845459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
    Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
    J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical organogels prepared from aromatic amino acid derivatives.
    Bastiat G; Leroux JC
    J Mater Chem; 2009 Apr; 19(23):3867-3877. PubMed ID: 27099412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials.
    Du X; Zhou J; Shi J; Xu B
    Chem Rev; 2015 Dec; 115(24):13165-307. PubMed ID: 26646318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ forming polymeric drug delivery systems.
    Madan M; Bajaj A; Lewis S; Udupa N; Baig JA
    Indian J Pharm Sci; 2009 May; 71(3):242-51. PubMed ID: 20490289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease.
    Bastiat G; Plourde F; Motulsky A; Furtos A; Dumont Y; Quirion R; Fuhrmann G; Leroux JC
    Biomaterials; 2010 Aug; 31(23):6031-8. PubMed ID: 20472283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid as a depot for the formulation of long-acting drugs.
    Maji SK; Schubert D; Rivier C; Lee S; Rivier JE; Riek R
    PLoS Biol; 2008 Feb; 6(2):e17. PubMed ID: 18254658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ-forming oleogel implant for rivastigmine delivery.
    Vintiloiu A; Lafleur M; Bastiat G; Leroux JC
    Pharm Res; 2008 Apr; 25(4):845-52. PubMed ID: 17694395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs.
    Plourde F; Motulsky A; Couffin-Hoarau AC; Hoarau D; Ong H; Leroux JC
    J Control Release; 2005 Nov; 108(2-3):433-41. PubMed ID: 16182402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants.
    Motulsky A; Lafleur M; Couffin-Hoarau AC; Hoarau D; Boury F; Benoit JP; Leroux JC
    Biomaterials; 2005 Nov; 26(31):6242-53. PubMed ID: 15916802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits.
    Singh S; Singh J
    Int J Pharm; 2007 Jan; 328(1):42-8. PubMed ID: 16959451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organogels in drug delivery.
    Murdan S
    Expert Opin Drug Deliv; 2005 May; 2(3):489-505. PubMed ID: 16296770
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.